63
State, Brazil]. Cadernos de saude publica / Ministerio da Saude, Fundacao Oswaldo Cruz,
Escola Nacional de Saude Publica. 2007 May;23(5):1187-97.
[46] Oliveira ML, Pierro AP, Silveira PA, Campos MM, Vilela MF. Relapse of
lepromatous leprosy after WHO/MDT with rapid bacterial growth. Leprosy review. 2002
Dec;73(4):386-8.
[47] Ximenes RA, Gallo ME, Brito Mde F. Retreatment in leprosy: a case-control study.
Revista de saude publica. 2007 Aug;41(4):632-7.
[48] Daumerie D, Pannikar V. Issues in evaluating information on relapse in leprosy.
Indian journal of leprosy. 1995 Jan-Mar;67(1):27-33.
[49] Pereira Edos S, Cunha Mda G, Maroja Mde F, Tavares Tde M, Ibanez LS, Berbegal
MP, et al. Leprosy elimination campaign, Amazonas-Brazil 1997. Leprosy review. 2000
Mar;71(1):77-80.
[50] Jardim MR, Antunes SL, Santos AR, Nascimento OJ, Nery JA, Sales AM, et al.
Criteria for diagnosis of pure neural leprosy. Journal of neurology. 2003 Jul;250(7):806-9.
[51] ML O. Cura da hanseníase: magnitude das recidivas no Brasil, estudo de coorte de
diferentes esquemas terapêuticos e fatores de risco [Tese de Doutorado]. Rio de Janeiro:
Universidade Federal do Rio de Janeiro; 1996.
[52] Ebenezer GJ, Norman G, Joseph GA, Daniel S, Job CK. Drug resistant-
Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.
Indian journal of leprosy. 2002 Oct-Dec;74(4):301-12.
[53] Ji B. Rifampicin resistant leprosy: a review and a research proposal of a pilot study.
Leprosy review. 2002 Mar;73(1):2-8.
[54] Janin YL. Antituberculosis drugs: ten years of research. Bioorganic & medicinal
chemistry. 2007 Apr 1;15(7):2479-513.
[55] Jin DJ, Gross CA. Mapping and sequencing of mutations in the Escherichia coli rpoB
gene that lead to rifampicin resistance. Journal of molecular biology. 1988 Jul 5;202(1):45-58.
[56] Cambau E, Bonnafous P, Perani E, Sougakoff W, Ji B, Jarlier V. Molecular detection
of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary
leprosy. Clin Infect Dis. 2002 Jan 1;34(1):39-45.
[57] Honore N, Perrani E, Telenti A, Grosset J, Cole ST. A simple and rapid technique for
the detection of rifampin resistance in Mycobacterium leprae. Int J Lepr Other Mycobact Dis.
1993 Dec;61(4):600-4.
[58] Honore N, Cole ST. Molecular basis of rifampin resistance in Mycobacterium leprae.
Antimicrobial agents and chemotherapy. 1993 Mar;37(3):414-8.
[59] Williams DL, Waguespack C, Eisenach K, Crawford JT, Portaels F, Salfinger M, et al.
Characterization of rifampin-resistance in pathogenic mycobacteria. Antimicrobial agents and
chemotherapy. 1994 Oct;38(10):2380-6.
[60] Maeda S, Matsuoka M, Nakata N, Kai M, Maeda Y, Hashimoto K, et al. Multidrug
resistant Mycobacterium leprae from patients with leprosy. Antimicrobial agents and
chemotherapy. 2001 Dec;45(12):3635-9.
[61] Vinnicombe HG, Derrick JP. Dihydropteroate synthase: an old drug target revisited.
Biochemical Society transactions. 1999 Feb;27(2):53-8.
[62] Ji BH. Drug resistance in leprosy--a review. Leprosy review. 1985 Dec;56(4):265-78.
[63] Pearson JM, Rees RJ, Waters MF. Sulphone resistance in leprosy. A review of one
hundred proven clinical cases. Lancet. 1975 Jul 12;2(7924):69-72.
[64] Pettit JH, Rees RJ. Sulphone Resistance in Leprosy. an Experimental and Clinical
Study. Lancet. 1964 Sep 26;2(7361):673-4.
[65] Shepard CC, Tolentino JG, McRae DH. The therapeutic effect of 4,4'-diacetyldiamino-
diphenylsulfone (DADDS) in leprosy. The American journal of tropical medicine and
hygiene. 1968 Mar;17(2):192-201.
[66] Balraj V, Jesudasan K, Chacko CJ, Christian M, Taylor PM, Fritschi EP, et al.
Prevalence of secondary dapsone resistance in Gudiyattam Taluk, the leprosy control area of